Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tecnis ZCB00 IOL, Toric Intraocular lens · 1 trial · 1 indication
Reduction in cylinder postoperatively vs. preoperatively (baseline) as measured by keratometry and manifest refraction. Mean percent reduction in cylinder = (postoperative refractive cylinder minus preoperative keratometric cylinder)/(target refractive cylinder minus preoperative keratometric cylinder). Reduction in cylinder was assessed in the first eye (per participant) for contribution to the mean.
| Arm | Type | Description |
|---|---|---|
| Control IOL | ACTIVE_COMPARATOR | Approved Intraocular control lens |
| Toric IOL | EXPERIMENTAL | Investigational Toric IOL |
| Higher Cylinder Toric IOL | EXPERIMENTAL | Investigational Toric IOLs with higher cylinder powers. |
| Name | Type | Description |
|---|---|---|
| Tecnis ZCB00 IOL (control) | DEVICE | Tecnis 1-piece acrylic IOL |
| Toric Intraocular lens | DEVICE | Toric acrylic intraocular lens with various cylinder powers |
Inclusion Criteria: * Minimum 18 years of age * Cataract for which phacoemulsification extraction and posterior chamber IOL implantation has been planned for both eyes * Preoperative best corrected distance visual acuity (BCDVA)of 20/40 or worse (Snellen), with or without glare, for each eye * BCDV...
Tecnis ZCB00 IOL is a toric intraocular lens used for cataract treatment. It is designed to be implanted during cataract surgery to replace the eye's natural lens. The lens is intended to correct vision in patients with cataracts, and the toric design addresses astigmatism. It is currently in Phase 3 clinical development.
Tecnis ZCB00 IOL is developed by Abbott Laboratories, a company traded under the ticker ABT. The company is conducting clinical trials to evaluate the safety and effectiveness of this toric intraocular lens for cataract patients. The development program includes a Phase 3 study that has been completed.
Tecnis ZCB00 IOL is in Phase 3 clinical development. A Phase 3 trial has been completed to evaluate the lens in cataract patients. The study was randomized, double-blind, and active-controlled, with 269 participants enrolled. The lens is investigational and not yet approved for commercial use.
Tecnis ZCB00 IOL has one completed Phase 3 clinical trial, identified as NCT01098812, titled 'Clinical Evaluation of a 1-Piece Intraocular Lens.' The study enrolled 269 participants with cataracts, aged 18 years and older, and included healthy volunteers. The trial was randomized, double-blind, and active-controlled.
Yes, Tecnis ZCB00 IOL is a toric intraocular lens. The 'toric' designation means the lens has different powers in different meridians to correct astigmatism, in addition to replacing the cataract-affected natural lens. This design aims to improve visual outcomes for cataract patients with astigmatism.